NCT05548270View on ClinicalTrials.gov

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

PHASE3CompletedINTERVENTIONAL
Enrollment

503

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions
Motion Sickness
Interventions
DRUG

DPI-386 Nasal Gel

Subjects will self-administer DPI-386 Nasal Gel or Placebo

DRUG

Placebo

Subjects will self-administer DPI-386 Nasal Gel or Placebo

Trial Locations (1)

90404

Santa Monica Clinical Trials, Santa Monica

All Listed Sponsors
lead

Repurposed Therapeutics, Inc.

INDUSTRY